COVID-19
Pfizer and Moderna test COVID-19 vaccines against new strain
December 22, 2020Manufacturing and Production COVID-19, Moderna, Pfizer, Vaccine
Pfizer and Moderna have begun testing their COVID-19 vaccines against the new, fast-spreading strain of the virus that was recently …
EU gives green light to Pfizer-BioNTech COVID-19 vaccine
December 22, 2020Manufacturing and Production COVID-19, EMA, Pfizer, Vaccine
The EMA has recommended the Pfizer-BioNTech COVID-19 vaccine for use across the EU’s 27 countries, with the first doses set …
Moderna’s COVID-19 vaccine receives emergency approval from FDA
December 21, 2020Sales and Marketing COVID-19, FDA, Moderna, US, Vaccine
Moderna has announced that the FDA yesterday authorised the emergency use of mRNA-1273, the biotechnology company’s vaccine against COVID-19 in …
Top Ten most popular articles on Pharmafile.com this week
December 18, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Vaccine, antibody
The top news stories of the past week continue to centre around the COVID-19 pandemic; a new variant of the …
Regeneron announces initial clinical data for COVID-19 antibody cocktail
December 18, 2020Medical Communications COVID-19, Regeneron, antibody
Regeneron Pharmaceuticals has announced that initial clinical data published in the New England Journal of Medicine shows that its antibody …
Ena Respiratory’s nasal spray reduces COVID-19 replication by 96%
December 18, 2020Medical Communications COVID-19, Nasal Spray
Australian biotech Ena Respiratory has revealed that its self-administered nasal spray INNA-051, when taken once or twice weekly, reduced viral …
Novavax secures deal with New Zealand for 10.7m doses of COVID-19 vaccine
December 17, 2020Sales and Marketing COVID-19, Novavax, Vaccine
Novavax has announced an Advance Purchase Agreement with New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, the …
FDA says Pfizer vaccine vials contain extra doses, boosting US supply
December 17, 2020Sales and Marketing COVID-19, FDA, Pfizer, Vaccine
The FDA has announced that extra doses contained in Pfizer COVID-19 vaccine vials could expand America’s supply of the jab …
Quarter of the world may not access COVID-19 vaccine until 2022
December 16, 2020Research and Development COVID-19, Vaccine
Almost a quarter of the world’s population may not have access to a COVID-19 vaccine until 2022, according to a …
AbbVie buys COVID-19 antibody licence from Harbour BioMed
December 16, 2020Research and Development AbbVie, COVID-19, Harbour BioMed, antibody
Harbour BioMed (HBM) and Utrecht University (UU) have announced that their fully human, SARS-CoV-2 neutralising antibody 47D11 and programme, has …
UAE rolls out Sinopharm COVID-19 vaccine amid conflicting reports of efficacy
December 15, 2020Manufacturing and Production, Research and Development COVID-19, China, Sinopharm, UAE, coronavirus
The United Arab Emirates has begun rolling out Sinopharm’s COVID-19 vaccine in its capital Abu Dhabi, despite claims that numerous …
Final control point analysis shows 90% efficacy for Russia’s Sputnik V COVID-19 vaccine
December 15, 2020Manufacturing and Production, Research and Development COVID-19, Sputnik V, Vaccine
Efficacy data have been revealed from the final control point data analysis for Russia’s Sputnik V COVID-19 vaccine, showing the …
New coronavirus strain identified in the UK
December 15, 2020Manufacturing and Production, Research and Development COVID-19, UK, coronavirus, vaccines
A new variant of coronavirus has been identified in the UK, and is growing faster in some parts of England, …
FDA issues emergency use authorisation for Pfizer-BioNTech vaccine
December 14, 2020Sales and Marketing COVID-19, FDA, US, Vaccine
The US Food and Drug Administration has approved the Pfizer-BioNTech COVID-19 vaccine for emergency use in those aged 16 and …
Novartis and Incyte’s ruxolitinib fails to show benefit in COVID-19 at Phase 3
December 14, 2020Research and Development, Sales and Marketing COVID-19, Incyte, Novartis
Novartis has unveiled that its JAK 1/2 tyrosine kinase inhibitor ruxolitinib fell short of its main efficacy goal in the …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
